{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:29:38Z","timestamp":1786516178832,"version":"build-2736575974"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05157-x","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:44:37Z","timestamp":1786509877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2512-7491","authenticated-orcid":false,"given":"Asmaa Mohammad","family":"Ramadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0250-1709","authenticated-orcid":false,"given":"Lamia M.","family":"El-Wakeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdulMoneim","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-3434","authenticated-orcid":false,"given":"Sarah Farid","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"5157_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017.","journal-title":"J Hepatol"},{"key":"5157_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/metabo12111073","volume":"12","author":"T Bassal","year":"2022","unstructured":"Bassal T, Basheer M, Boulos M, Assy N. Nonalcoholic Fatty Liver Disease\u2014A Concise Review of Noninvasive Tests and Biomarkers. Metabolites. 2022;12:1073. https:\/\/doi.org\/10.3390\/metabo12111073.","journal-title":"Metabolites"},{"key":"5157_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatology"},{"key":"5157_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11010-019-03625-5","volume":"463","author":"Q Dong","year":"2020","unstructured":"Dong Q, Majumdar G, O\u2019Meally RN, Cole RN, Elam MB, Raghow R. Insulin-induced de novo lipid synthesis occurs mainly via mTOR-dependent regulation of proteostasis of SREBP-1c. Mol Cell Biochem. 2020;463:13\u201331. https:\/\/doi.org\/10.1007\/s11010-019-03625-5.","journal-title":"Mol Cell Biochem"},{"key":"5157_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116\u201341. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.025.","journal-title":"Free Radic Biol Med"},{"key":"5157_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"5157_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"5157_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","volume":"83","author":"MB Bansal","year":"2026","unstructured":"Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction\u2013associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83:1326\u201340. https:\/\/doi.org\/10.1097\/HEP.0000000000001608.","journal-title":"Hepatology"},{"key":"5157_CR9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis. N Engl J Med. 2025;392:2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"key":"5157_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"5157_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1136\/bmj.2.6198.1097","volume":"2","author":"LF Prescott","year":"1979","unstructured":"Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. BMJ. 1979;2:1097\u2013100. https:\/\/doi.org\/10.1136\/bmj.2.6198.1097.","journal-title":"BMJ"},{"key":"5157_CR12","unstructured":"Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H et al. ORIGINAL A RTICLE N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease. 2010."},{"key":"5157_CR13","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1046\/j.1440-1746.2003.03156.x","volume":"18","author":"G Emel Pamuk","year":"2003","unstructured":"Emel Pamuk G, Sonsuz A. N-Acetylcysteine in The Treatment Of Non\u2010Alcoholic Steatohepatitis. J Gastroenterol Hepatol. 2003;18:1220\u20131. https:\/\/doi.org\/10.1046\/j.1440-1746.2003.03156.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"5157_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1872-034X.2007.00215.x","volume":"38","author":"CPMS De Oliveira","year":"2008","unstructured":"De Oliveira CPMS, Stefano JT, De Siqueira ERF, Silva LS, De Campos Mazo DF, Lima VMR, et al. Combination of N -acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non\u2010alcoholic steatohepatitis. Hepatol Res. 2008;38:159\u201365. https:\/\/doi.org\/10.1111\/j.1872-034X.2007.00215.x.","journal-title":"Hepatol Res"},{"key":"5157_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1590\/s0004-2803.201900000-36","volume":"56","author":"CP OLIVEIRA","year":"2019","unstructured":"OLIVEIRA CP, COTRIM HP, STEFANO JT, SIQUEIRA ACG, SALGADO ALA, PARISE ER, N-ACETYLCYSTEINE AND\/OR URSODEOXYCHOLIC ACID ASSOCIATED, WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. Arq Gastroenterol. 2019;56:184\u201390. https:\/\/doi.org\/10.1590\/s0004-2803.201900000-36.","journal-title":"Arq Gastroenterol"},{"key":"5157_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/jpn3.12312","volume":"79","author":"P Babu Balagopal","year":"2024","unstructured":"Babu Balagopal P, Kohli R, Uppal V, Averill L, Shah C, McGoogan K, et al. Effect of N -acetyl cysteine in children with metabolic dysfunction\u2010associated steatotic liver disease\u2014A pilot study. J Pediatr Gastroenterol Nutr. 2024;79:652\u201360. https:\/\/doi.org\/10.1002\/jpn3.12312.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5157_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40264-020-01026-y","volume":"44","author":"P Calverley","year":"2021","unstructured":"Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021;44:273\u201390. https:\/\/doi.org\/10.1007\/s40264-020-01026-y.","journal-title":"Drug Saf"},{"key":"5157_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ph15020217","volume":"15","author":"M Guerini","year":"2022","unstructured":"Guerini M, Condr\u00f2 G, Friuli V, Maggi L, Perugini P. N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review. Pharmaceuticals. 2022;15:217. https:\/\/doi.org\/10.3390\/ph15020217.","journal-title":"Pharmaceuticals"},{"key":"5157_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, Fan J-G, Mi Y-Q, de L\u00e9dinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022.","journal-title":"J Hepatol"},{"key":"5157_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1741-7015-12-112","volume":"12","author":"A Trichopoulou","year":"2014","unstructured":"Trichopoulou A, Mart\u00ednez-Gonz\u00e1lez MA, Tong TY, Forouhi NG, Khandelwal S, Prabhakaran D, et al. Definitions and potential health benefits of the Mediterranean diet: views from experts around the world. BMC Med. 2014;12:112. https:\/\/doi.org\/10.1186\/1741-7015-12-112.","journal-title":"BMC Med"},{"key":"5157_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139. https:\/\/doi.org\/10.1007\/BF00280883.","journal-title":"Diabetologia"},{"key":"5157_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/liv.13391","volume":"37","author":"ZM Younossi","year":"2017","unstructured":"Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non\u2010alcoholic fatty liver disease and non\u2010alcoholic steatohepatitis: <scp>CLDQ \u2010 NAFLD<\/scp>. Liver Int. 2017;37:1209\u201318. https:\/\/doi.org\/10.1111\/liv.13391.","journal-title":"Liver Int"},{"key":"5157_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association Declaration of Helsinki","year":"2025","unstructured":"World Medical Association Declaration of Helsinki. JAMA. 2025;333:71. https:\/\/doi.org\/10.1001\/jama.2024.21972.","journal-title":"JAMA"},{"key":"5157_CR24","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","volume":"23","author":"X Guo","year":"2022","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int J Mol Sci. 2022;23:15489. https:\/\/doi.org\/10.3390\/ijms232415489.","journal-title":"Int J Mol Sci"},{"key":"5157_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2174\/1570159X19666201230144109","volume":"19","author":"G Raghu","year":"2021","unstructured":"Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2021;19:1202\u201324. https:\/\/doi.org\/10.2174\/1570159X19666201230144109.","journal-title":"Curr Neuropharmacol"},{"key":"5157_CR26","doi-asserted-by":"publisher","DOI":"10.20960\/nh.04635","author":"E Garicano Vilar","year":"2023","unstructured":"Garicano Vilar E, Sanz Rojo S, L\u00f3pez Oliva S, Mart\u00ednez S, Terr\u00e9n Lora A, San Mauro Martin I. Effect of MetioNac\u00ae in patients with metabolic syndrome who are at risk of metabolic dysfunction associated fatty liver disease: a randomized controlled trial. Nutr Hosp. 2023. https:\/\/doi.org\/10.20960\/nh.04635.","journal-title":"Nutr Hosp"},{"key":"5157_CR27","doi-asserted-by":"publisher","first-page":"105299","DOI":"10.1016\/j.jff.2022.105299","volume":"99","author":"Y Panahi","year":"2022","unstructured":"Panahi Y, Ostadmohammadi V, Raygan F, Sharif MR, Sahebkar A. The effects of N-acetylcysteine administration on metabolic status and serum adiponectin levels in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial. J Funct Foods. 2022;99:105299. https:\/\/doi.org\/10.1016\/j.jff.2022.105299.","journal-title":"J Funct Foods"},{"key":"5157_CR28","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.34172\/ahj.1667","volume":"17","author":"M Sinaeinejad","year":"2025","unstructured":"Sinaeinejad M, Karimi M, Razavizadeh M, Arj A, Tabatabaei SH, Mortezazadeh M, et al. Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial. Addict Health. 2025;17:1667. https:\/\/doi.org\/10.34172\/ahj.1667.","journal-title":"Addict Health"},{"key":"5157_CR29","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.3748\/wjg.v13.i38.5127","volume":"13","author":"D Thong-Ngam","year":"2007","unstructured":"Thong-Ngam D. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J Gastroenterol. 2007;13:5127. https:\/\/doi.org\/10.3748\/wjg.v13.i38.5127.","journal-title":"World J Gastroenterol"},{"key":"5157_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00595-008-3930-4","volume":"39","author":"MA Uzun","year":"2009","unstructured":"Uzun MA, Koksal N, Kadioglu H, Gunerhan Y, Aktas S, Dursun N, et al. Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease. Surg Today. 2009;39:592\u20137. https:\/\/doi.org\/10.1007\/s00595-008-3930-4.","journal-title":"Surg Today"},{"key":"5157_CR31","doi-asserted-by":"publisher","unstructured":"Ali MHH, Messiha BAS, Abdel-Latif HA-T. Protective effect of ursodeoxycholic acid, resveratrol, and N -acetylcysteine on nonalcoholic fatty liver disease in rats. Pharm Biol. 2015;1\u201311. https:\/\/doi.org\/10.3109\/13880209.2015.1060247.","DOI":"10.3109\/13880209.2015.1060247"},{"key":"5157_CR32","doi-asserted-by":"publisher","first-page":"173368","DOI":"10.1016\/j.ejphar.2020.173368","volume":"884","author":"AH Faghfouri","year":"2020","unstructured":"Faghfouri AH, Zarezadeh M, Tavakoli-Rouzbehani OM, Radkhah N, Faghfuri E, Kord-Varkaneh H, et al. The effects of N-acetylcysteine on inflammatory and oxidative stress biomarkers: A systematic review and meta-analysis of controlled clinical trials. Eur J Pharmacol. 2020;884:173368. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173368.","journal-title":"Eur J Pharmacol"},{"key":"5157_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/156652409787847191","volume":"9","author":"S Polyzos","year":"2009","unstructured":"Polyzos S, Kountouras J, Zavos C. Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines. Curr Mol Med. 2009;9:299\u2013314. https:\/\/doi.org\/10.2174\/156652409787847191.","journal-title":"Curr Mol Med"},{"key":"5157_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","volume":"56","author":"S Zelber-Sagi","year":"2012","unstructured":"Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.011.","journal-title":"J Hepatol"},{"key":"5157_CR35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/gut.2009.205088","volume":"59","author":"VW-S Wong","year":"2010","unstructured":"Wong VW-S, Wong GL-H, Choi PC-L, Chan AW-H, Li MK-P, Chan H-Y, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969\u201374. https:\/\/doi.org\/10.1136\/gut.2009.205088.","journal-title":"Gut"},{"key":"5157_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1071\/RD14182","volume":"28","author":"E Cheraghi","year":"2016","unstructured":"Cheraghi E, Mehranjani MS, Shariatzadeh MA, Esfahani MHN, Ebrahimi Z. N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reprod Fertil Dev. 2016;28:723. https:\/\/doi.org\/10.1071\/RD14182.","journal-title":"Reprod Fertil Dev"},{"key":"5157_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jogoh.2017.07.004","volume":"46","author":"M Nemati","year":"2017","unstructured":"Nemati M, Nemati S, Taheri A-M, Heidari B. Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. J Gynecol Obstet Hum Reprod. 2017;46:579\u201385. https:\/\/doi.org\/10.1016\/j.jogoh.2017.07.004.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"5157_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/09513590.2015.1115974","volume":"32","author":"F Javanmanesh","year":"2016","unstructured":"Javanmanesh F, Kashanian M, Rahimi M, Sheikhansari N. A comparison between the effects of metformin and N -acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome. Gynecol Endocrinol. 2016;32:285\u20139. https:\/\/doi.org\/10.3109\/09513590.2015.1115974.","journal-title":"Gynecol Endocrinol"},{"key":"5157_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejogrb.2011.07.005","volume":"159","author":"G Oner","year":"2011","unstructured":"Oner G, Muderris II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reproductive Biology. 2011;159:127\u201331. https:\/\/doi.org\/10.1016\/j.ejogrb.2011.07.005.","journal-title":"Eur J Obstet Gynecol Reproductive Biology"},{"key":"5157_CR40","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jdiacomp.2016.02.003","volume":"30","author":"MA Szkudlinska","year":"2016","unstructured":"Szkudlinska MA, von Frankenberg AD, Utzschneider KM. The antioxidant N-Acetylcysteine does not improve glucose tolerance or \u03b2-cell function in type 2 diabetes. J Diabetes Complications. 2016;30:618\u201322. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.02.003.","journal-title":"J Diabetes Complications"},{"key":"5157_CR41","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled Attenuation Parameter (CAP): A Novel VCTE\u2122 Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes. Ultrasound Med Biol. 2010;36:1825\u201335. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2010.07.005.","journal-title":"Ultrasound Med Biol"},{"key":"5157_CR42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4103\/1735-5362.192487","volume":"11","author":"N El-Lakkany","year":"2016","unstructured":"El-Lakkany N, Seif el-Din S, Sabra A-N-A, Hammam O, Ebeid F-L. Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver. Res Pharm Sci. 2016;11:374. https:\/\/doi.org\/10.4103\/1735-5362.192487.","journal-title":"Res Pharm Sci"},{"key":"5157_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12944-020-01274-y","volume":"19","author":"C-C Tsai","year":"2020","unstructured":"Tsai C-C, Chen Y-J, Yu H-R, Huang L-T, Tain Y-L, Lin I-C, et al. Long term N-acetylcysteine administration rescues liver steatosis via endoplasmic reticulum stress with unfolded protein response in mice. Lipids Health Dis. 2020;19:105. https:\/\/doi.org\/10.1186\/s12944-020-01274-y.","journal-title":"Lipids Health Dis"},{"key":"5157_CR44","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.tjnut.2023.03.038","volume":"153","author":"V Gao","year":"2023","unstructured":"Gao V, Long MT, Singh SR, Kim Y, Zhang X, Rogers G, et al. A Healthy Diet is Associated with a Lower Risk of Hepatic Fibrosis. J Nutr. 2023;153:1587\u201396. https:\/\/doi.org\/10.1016\/j.tjnut.2023.03.038.","journal-title":"J Nutr"},{"key":"5157_CR45","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3390\/nu15133018","volume":"15","author":"N Perez-Diaz-del-Campo","year":"2023","unstructured":"Perez-Diaz-del-Campo N, Castelnuovo G, Rosso C, Nicolosi A, Guariglia M, Dileo E, et al. Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD. Nutrients. 2023;15:3018. https:\/\/doi.org\/10.3390\/nu15133018.","journal-title":"Nutrients"},{"key":"5157_CR46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12072-014-9573-1","volume":"8","author":"G Ferraioli","year":"2014","unstructured":"Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Rondanelli M, Perani G, et al. Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis. Hepatol Int. 2014;8:576\u201381. https:\/\/doi.org\/10.1007\/s12072-014-9573-1.","journal-title":"Hepatol Int"},{"key":"5157_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","volume":"13","author":"EB Tapper","year":"2015","unstructured":"Tapper EB, Castera L, Afdhal NH. FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clin Gastroenterol Hepatol. 2015;13:27\u201336. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.039.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5157_CR48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/hepr.12649","volume":"46","author":"N Fujimori","year":"2016","unstructured":"Fujimori N, Tanaka N, Shibata S, Sano K, Yamazaki T, Sekiguchi T, et al. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none\u2010to\u2010mild obesity and liver fibrosis. Hepatol Res. 2016;46:1019\u201327. https:\/\/doi.org\/10.1111\/hepr.12649.","journal-title":"Hepatol Res"},{"key":"5157_CR49","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jgh.12557","volume":"29","author":"W Chan","year":"2014","unstructured":"Chan W, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29:1470\u20136. https:\/\/doi.org\/10.1111\/jgh.12557.","journal-title":"J Gastroenterol Hepatol"},{"key":"5157_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2.","journal-title":"Hepatol Int"},{"key":"5157_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Disease. 2010;42:503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Disease"},{"key":"5157_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12906-024-04692-y","volume":"25","author":"MK Shaker","year":"2025","unstructured":"Shaker MK, Hassany M, Eysa B, Adel A, Zidan A, Mohamed S. The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex\u00ae) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial. BMC Complement Med Ther. 2025;25:8. https:\/\/doi.org\/10.1186\/s12906-024-04692-y.","journal-title":"BMC Complement Med Ther"},{"key":"5157_CR53","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3390\/molecules29194576","volume":"29","author":"AM Garc\u00eda-Mu\u00f1oz","year":"2024","unstructured":"Garc\u00eda-Mu\u00f1oz AM, Victoria-Montesinos D, Ballester P, Cerd\u00e1 B, Zafrilla P. A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin. Molecules. 2024;29:4576. https:\/\/doi.org\/10.3390\/molecules29194576.","journal-title":"Molecules"},{"key":"5157_CR54","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/ph18050650","volume":"18","author":"AY Zakaria","year":"2025","unstructured":"Zakaria AY, Badawi R, Osama H, Abdelrahman MA, El-Kalaawy AM. A Comparative Study of N-Acetyl Cysteine, Rosuvastatin, and Vitamin E in the Management of Patients with Non-Alcoholic Steatohepatitis: A Randomized Controlled Trial. Pharmaceuticals. 2025;18:650. https:\/\/doi.org\/10.3390\/ph18050650.","journal-title":"Pharmaceuticals"},{"key":"5157_CR55","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71:808\u201319. https:\/\/doi.org\/10.1002\/hep.31014.","journal-title":"Hepatology"},{"key":"5157_CR56","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","volume":"42","author":"A Deprince","year":"2020","unstructured":"Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092. https:\/\/doi.org\/10.1016\/j.molmet.2020.101092.","journal-title":"Mol Metab"},{"key":"5157_CR57","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/met.2020.0017","volume":"18","author":"M Rani","year":"2020","unstructured":"Rani M, Aggarwal R, Vohra K. Effect of N-Acetylcysteine on Metabolic Profile in Metabolic Syndrome Patients. Metab Syndr Relat Disord. 2020;18:341\u20136. https:\/\/doi.org\/10.1089\/met.2020.0017.","journal-title":"Metab Syndr Relat Disord"},{"key":"5157_CR58","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/nu9080870","volume":"9","author":"L Abenavoli","year":"2017","unstructured":"Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, et al. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients. 2017;9:870. https:\/\/doi.org\/10.3390\/nu9080870.","journal-title":"Nutrients"},{"key":"5157_CR59","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1586\/17474124.2015.1004312","volume":"9","author":"L Abenavoli","year":"2015","unstructured":"Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, et al. Effects of Mediterranean diet supplemented with silybin\u2013vitamin E\u2013phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:519\u201327. https:\/\/doi.org\/10.1586\/17474124.2015.1004312.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5157_CR60","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.016.","journal-title":"J Hepatol"},{"key":"5157_CR61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367\u2013e3785. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","journal-title":"Gastroenterology"},{"key":"5157_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals. Expert Rev Gastroenterol. 2022;163:764\u2013e7741. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.023.","journal-title":"Expert Rev Gastroenterol"},{"key":"5157_CR63","doi-asserted-by":"publisher","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism. 2021;115:154455. https:\/\/doi.org\/10.1016\/j.metabol.2020.154455.","journal-title":"Metabolism"},{"key":"5157_CR64","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep.28416","volume":"63","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, Lai M. Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study. Hepatology. 2016;63:1184\u20139. https:\/\/doi.org\/10.1002\/hep.28416.","journal-title":"Hepatology"},{"key":"5157_CR65","doi-asserted-by":"publisher","first-page":"e0263931","DOI":"10.1371\/journal.pone.0263931","volume":"17","author":"T Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez T, Vi\u00f1uela M, Vidal C, Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE. 2022;17:e0263931. https:\/\/doi.org\/10.1371\/journal.pone.0263931.","journal-title":"PLoS ONE"},{"key":"5157_CR66","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3390\/nu11122971","volume":"11","author":"MC Plaz Torres","year":"2019","unstructured":"Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, et al. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients. 2019;11:2971. https:\/\/doi.org\/10.3390\/nu11122971.","journal-title":"Nutrients"},{"key":"5157_CR67","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.phanu.2020.100238","volume":"14","author":"M Zarei","year":"2020","unstructured":"Zarei M, Zarezadeh M, Khademi F, Adeli S, Abbaszade F, Nikpayam O, et al. What are the effects of N-acetylcysteine supplementation on anthropometric indices? A systematic review and meta-analysis of clinical trials. PharmaNutrition. 2020;14:100238. https:\/\/doi.org\/10.1016\/j.phanu.2020.100238.","journal-title":"PharmaNutrition"},{"key":"5157_CR68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/j.gastro.2017.03.005","volume":"153","author":"P Nasr","year":"2017","unstructured":"Nasr P, Forsgren MF, Ignatova S, Dahlstr\u00f6m N, Cedersund G, Leinhard OD, et al. Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. Gastroenterology. 2017;153:53\u2013e557. https:\/\/doi.org\/10.1053\/j.gastro.2017.03.005.","journal-title":"Gastroenterology"},{"key":"5157_CR69","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/antiox9121283","volume":"9","author":"PV Dludla","year":"2020","unstructured":"Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, Nyambuya TM, Marcheggiani F, Cirilli I, et al. N-Acetyl Cysteine Targets Hepatic Lipid Accumulation to Curb Oxidative Stress and Inflammation in NAFLD: A Comprehensive Analysis of the Literature. Antioxidants. 2020;9:1283. https:\/\/doi.org\/10.3390\/antiox9121283.","journal-title":"Antioxidants"},{"key":"5157_CR70","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/liv.13706","volume":"38","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, et al. Improvement of hepatic fibrosis and patient-reported outcomes in non\u2010alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018;38:1849\u201359. https:\/\/doi.org\/10.1111\/liv.13706.","journal-title":"Liver Int"},{"key":"5157_CR71","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jhep.2013.12.018","volume":"60","author":"V de L\u00e9dinghen","year":"2014","unstructured":"de L\u00e9dinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart J-B, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. J Hepatol. 2014;60:1026\u201331. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.018.","journal-title":"J Hepatol"},{"key":"5157_CR72","doi-asserted-by":"publisher","unstructured":"Carvalhana S, Leit\u00e3o J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int. 2014;34. https:\/\/doi.org\/10.1111\/liv.12305.","DOI":"10.1111\/liv.12305"},{"key":"5157_CR73","doi-asserted-by":"publisher","unstructured":"Kholy E, Ribaldone G, Paolo Caviglia G, Al-Shargi A, El Kholy AA, Adel A et al. Citation: Academic Editors: Davide Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. 2023. https:\/\/doi.org\/10.3390\/biomedicines11110000","DOI":"10.3390\/biomedicines11110000"},{"key":"5157_CR74","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/egh.11.21","volume":"5","author":"RC Harmon","year":"2011","unstructured":"Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2011;5:189\u2013200. https:\/\/doi.org\/10.1586\/egh.11.21.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5157_CR75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2003.06.028","volume":"97","author":"P Avanzas","year":"2004","unstructured":"Avanzas P, Quiles J, de S\u00e1 EL, S\u00e1nchez A, Rubio R, Garc\u0131\u0301a E, et al. Neutrophil count and infarct size in patients with acute myocardial infarction. Int J Cardiol. 2004;97:155\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2003.06.028.","journal-title":"Int J Cardiol"},{"key":"5157_CR76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1478-3231.2011.02639.x","volume":"32","author":"N Alkhouri","year":"2012","unstructured":"Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297\u2013302. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02639.x.","journal-title":"Liver Int"},{"key":"5157_CR77","unstructured":"Yilmaz H, Serkan Yalcin K, Namuslu M, Celik HT, Sozen M, Inan O et al. Neutrophil-Lymphocyte Ratio (NLR) Could Be Better Predictor than C-reactive Protein (CRP) for Liver Fibrosis in Non-alcoholic Steatohepatitis(NASH). 2015."},{"key":"5157_CR78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/DMSO.S330526","volume":"15","author":"CRA Lesmana","year":"2022","unstructured":"Lesmana CRA, Kencana Y, Rinaldi I, Kurniawan J, Hasan I, Sulaiman AS, et al. Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). Diabetes Metabolic Syndrome Obes. 2022;15:15\u201322. https:\/\/doi.org\/10.2147\/DMSO.S330526.","journal-title":"Diabetes Metabolic Syndrome Obes"},{"key":"5157_CR79","doi-asserted-by":"publisher","unstructured":"Essa Ahmed S, Maher FT, Ahmed Naji N. Effect of Leptin and Oxidative Stress in the Blood of Obese Individuals. Biochem Anal Biochem. 2016;5. https:\/\/doi.org\/10.4172\/2161-1009.1000288.","DOI":"10.4172\/2161-1009.1000288"},{"key":"5157_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0149-2918(00)88479-9","volume":"22","author":"EM Grandjean","year":"2000","unstructured":"Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000;22:209\u201321. https:\/\/doi.org\/10.1016\/S0149-2918(00)88479-9.","journal-title":"Clin Ther"},{"key":"5157_CR81","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"M Demedts","year":"2005","unstructured":"Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2005;353:2229\u201342. https:\/\/doi.org\/10.1056\/NEJMoa042976.","journal-title":"N Engl J Med"},{"key":"5157_CR82","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder\u2014A Double-Blind Randomized Placebo-Controlled Trial. Biol Psychiatry. 2008;64:468\u201375. https:\/\/doi.org\/10.1016\/j.biopsych.2008.04.022.","journal-title":"Biol Psychiatry"},{"key":"5157_CR83","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1517\/14728220802517901","volume":"8","author":"S Dodd","year":"2008","unstructured":"Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N -acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther. 2008;8:1955\u201362. https:\/\/doi.org\/10.1517\/14728220802517901.","journal-title":"Expert Opin Biol Ther"},{"key":"5157_CR84","doi-asserted-by":"publisher","unstructured":"Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences. 2006;103:4628\u201333. https:\/\/doi.org\/10.1073\/pnas.0511304103","DOI":"10.1073\/pnas.0511304103"},{"key":"5157_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jcf.2014.09.015","volume":"14","author":"M Skov","year":"2015","unstructured":"Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen P\u00d8, Johansen HK, et al. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection \u2014 A pilot study. J Cyst Fibros. 2015;14:211\u20138. https:\/\/doi.org\/10.1016\/j.jcf.2014.09.015.","journal-title":"J Cyst Fibros"},{"key":"5157_CR86","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54322","author":"AD Harlivasari","year":"2024","unstructured":"Harlivasari AD, Susanto AD, Taufik FF, Ginting TT. The Role of Twice-Daily N-acetylcysteine (NAC) 2400\u00a0mg in Smoking Cessation: A Randomized, Placebo-Controlled Trial in Indonesia. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.54322.","journal-title":"Cureus"},{"key":"5157_CR87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11:27\u201337. https:\/\/doi.org\/10.5009\/gnl15502.","journal-title":"Gut Liver"},{"key":"5157_CR88","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749\u201356. https:\/\/doi.org\/10.1136\/gutjnl-2015-310861.","journal-title":"Gut"},{"key":"5157_CR89","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang Y-X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152:706\u201315. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.031.","journal-title":"Gastroenterology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05157-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05157-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05157-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:50:46Z","timestamp":1786513846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05157-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5157"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05157-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ain Shams University Ethical Review Board (Approval No. RHDIRB2020110301 REC # 114). Also, the Research and Ethics Committee approved it for Experimental and Clinical Studies, NHTMRI (Approval No. 2\/22) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. In addition, it was registered at clinicaltrials.gov (\n                      \n                      ) on October 2022. Written informed consent was obtained from all participants prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"500"}}